Product image of Imipenem/Cilastatin Kabi (Cilastatin Sodium, Imipenem Monohydrate) supplied by GNH India

Imipenem/Cilastatin Kabi

Active Ingredient:
Cilastatin Sodium, Imipenem Monohydrate
Origin:
EU

Imipenem/Cilastatin Kabi (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem, the active ingredient in Imipenem/Cilastatin Kabi, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, urinary tract infections, skin and soft‑tissue infections, lower respiratory tract infections, meningitis, and sepsis in hospitalized patients.

GNH India supplies Imipenem/Cilastatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Fresenius Kabi S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

  • Complicated intra‑abdominal infections: provides rapid bacterial eradication in severe abdominal sepsis.
  • Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis.
  • Skin and soft‑tissue infections: treats deep tissue infections including necrotizing fasciitis.
  • Lower respiratory tract infections (including pneumonia): covers Gram‑negative and Gram‑positive pathogens in hospital‑acquired pneumonia.
  • Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.
  • Severe sepsis and septic shock: offers life‑saving coverage for polymicrobial infections.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting the final stages of bacterial cell‑wall peptidoglycan synthesis, which leads to cell lysis. Cilastatin, co‑administered, blocks renal dehydropeptidase I, preventing enzymatic degradation of imipenem and thereby maintaining therapeutic plasma concentrations.

Side Effects

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects

  • Nausea: mild gastrointestinal upset.
  • Diarrhea: may be watery or loose.
  • Rash: mild skin erythema.
  • Elevated liver enzymes: transient increase in transaminases.
  • Injection site pain: discomfort at the infusion site.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment or CNS disorders.
  • Anaphylaxis: severe hypersensitivity reaction.
  • Clostridioides difficile colitis: antibiotic‑associated diarrhea.
  • Thrombocytopenia: reduced platelet count.
  • Renal dysfunction: worsening kidney function in susceptible individuals.

Precautions & Warnings

Use Imipenem/Cilastatin with careful clinical assessment and monitoring.

  • Renal impairment: adjust dose based on creatinine clearance.
  • History of seizures: avoid or monitor closely for neurotoxicity.
  • Hypersensitivity: discontinue if allergic reaction occurs.
  • Concomitant valproic acid: monitor for reduced antiepileptic levels.
  • Neonates and infants: use only when benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Drug interactions can affect efficacy or safety of Imipenem/Cilastatin.

Major Interactions (Avoid)

  • Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough.
  • Warfarin: may enhance anticoagulant effect, increasing INR.
  • Probenecid: can increase imipenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor electrolytes and renal function.
  • Other nephrotoxic agents (e.g., aminoglycosides): watch for additive kidney injury.
  • Antacids containing magnesium or aluminum: may affect absorption if oral formulations were used (not applicable to IV).

Frequently Asked Questions

Imipenem/Cilastatin Kabi is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, lower respiratory tract infections including pneumonia, bacterial meningitis, and severe sepsis or septic shock in hospitalized patients.

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing peptidoglycan cross‑linking and causing cell lysis. Cilastatin is co‑administered to inhibit renal dehydropeptidase I, which would otherwise degrade imipenem, thereby preserving its antibacterial activity.

The dosage of Imipenem/Cilastatin Kabi is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. The prescriber sets the exact dose and infusion schedule.

Safety data for Imipenem/Cilastatin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Imipenem/Cilastatin offers a broad spectrum of activity against many Gram‑negative, Gram‑positive, and anaerobic bacteria, similar to other carbapenems like meropenem. Its unique combination with cilastatin protects the drug from renal degradation, allowing higher plasma concentrations without additional renal toxicity.

The product should be stored refrigerated at 2‑8 °C, protected from light. It must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under the same temperature conditions.

Imipenem/Cilastatin Kabi is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central vein, typically over a 30‑ to 60‑minute infusion period, according to the prescriber's instructions.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid without appropriate monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin Sodium, Imipenem Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT